Commentary on “Costs of pharmacotherapy of chronic obstructive pulmonary disease in relation to changing Global Initiative for Chronic Obstructive Lung Disease guidelines (2007, 2011, and 2017 updates)”

摘要

Chronic obstructive pulmonary disease (COPD)is a complex and heterogenous disorder, charac?terized by high morbidity and mortality rates.1 Itrepresents a major social and economic burden forhealthcare systems worldwide.2 The reduction ofrisk factors, treatment of comorbidities, and pre?vention of acute exacerbations are key elementsof proper disease management.